Immunotherapy for Tauopathies
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Pathological tau protein is found in Alzheimer's disease and related tauopathies. The protein is hyperphosphorylated and/or mutated which leads to aggregation and neurotoxicity. Because cognitive functions correlate well with the degree of tau pathology, clearing these aggregates is a promising therapeutic approach. Studies pioneered by our laboratory and confirmed by others have shown that both active and passive immunizations targeting disease-related tau epitopes successfully reduce tau aggregates in vivo and slow or prevent behavioral impairments in mouse models of tauopathy. Here, we summarize recent advances in this new field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803 · cited 1×
“Importantly, extracellular tau aggregates appear to be taken up into cells/neurons, induce intracellular tau misfolding and thus spread tau pathology throughout the brain (Frost et al. 2009; Clavaguera et al. 2009).”
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“…and Aβ pathologies may have synergetic effects resulting in neurodegeneration (Frautschy et al. 1991; Sigurdsson et al. 1996, 1997; Gotz et al. 2001; Lewis et al. 2001; Ribe et al. 2005; Pearson and Powell 1989; Delacourte et al. 2002; Roberson et al. 2007), tackling both pathologies is likely to…”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 2×
“Considering that tau and Aβ pathologies may have synergetic effects resulting in neurodegeneration (Frautschy et al. 1991; Sigurdsson et al. 1996, 1997; Gotz et al. 2001; Lewis et al. 2001; Ribe et al. 2005; Pearson and Powell 1989; Delacourte et al. 2002; Roberson et al. 2007), tackling both pathologies is likely to…”
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“In the first active immunization trial, AN1792, clearance of Aβ plaques from the brain did not appear to slow the progression of dementia (Holmes et al. 2008).”
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 1×
“This mutation was originally identified in FTD patients as a causative factor in the disease, and the homozygous mice we employed exhibit pre-tangles, NFTs, neuronal loss, and motor deficits (Lewis et al. 2000).”
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“Safety of tau immunotherapy has not been thoroughly studied but is of a concern as with any other self immunogen, particularly considering the adverse reactions in the Aβ immunotherapy trials (Orgogozo et al. 2003; Kerchner and Boxer 2010).”
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Both active and passive immunizations to clear Aβ have shown encouraging results in animal studies (Schenk et al. 1999; Bard et al. 2000; Janus et al. 2000; Morgan et al. 2000; Sigurdsson et al. 2001, 2004; DeMattos et al. 2001; Das et al. 2003; Lemere and Masliah 2010).”
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 1×
“Importantly, extracellular tau aggregates appear to be taken up into cells/neurons, induce intracellular tau misfolding and thus spread tau pathology throughout the brain (Frost et al. 2009; Clavaguera et al. 2009).”
Cited by
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
“…using phosphorylated tau fragments (Asuni et al., 2007; Boimel et al., 2010; Bi et al., 2011), and passive vaccination using antibodies directed against NFT-associated tau phosphoepitopes (Boutajangout et al., 2011; Chai et al., 2011; Gu and Sigurdsson, 2011) have been reported in animal models.”
BackgroundThe role of extracellular Tau in the spreading of neurofibrillary pathology
Medina, M., & Avila, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00113 · Cited by 161
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
“…tau aggregates in vivo and slow or prevent behavioral deficits in mouse models of tauopathy (Asuni et al., 2007; Boutajangout et al., 2011; Boutajangout et al., 2010; Chai et al., 2011; Gu & Sigurdsson, 2011; Lasagna-Reeves et al., 2011; Troquier et al., 2012; Wisniewski & Boutajangout, 2010).”
BackgroundDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Metadata
- Authors
- Gu, J., & Sigurdsson, E. M.
- Venue
- Journal of Molecular Neuroscience
- Published
- 2011-07-08
- Volume
- 45
- Issue
- 3
- Pages
- 690-695
- ISSN
- 0895-8696 (ISSN-L)
- 1559-1166
- OpenAlex
- W2077475987
- Cited by
- 34
- References
- 24
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy for Tauopathies. https://app.cochat.ai/papers/10.1007/s12031-011-9576-5
- The paper
- Gu, J., & Sigurdsson, E. M. (2011). Immunotherapy for Tauopathies. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-011-9576-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.